A review on leukemia: advances in diagnosis, treatment and prognosis

  • N. Hemalatha B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
  • M. Sowjanya Assistant professor, Department of Pharmacy practice , Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
  • Y. Prapurna Chandra Principal and Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
  • Venugopalaiah Penabaka Professor & HOD, Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
  • Yerikala Ramesh Professor, Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.

Abstract

Cancer is a disease of altered signalling and metabolism, causing uncontrolled division and survival of transformed cells. A host of molecules, factors, and conditions have been designated as underlying causes for the inception and progression of the disease. An enormous amount of data is available, system-wide interaction networks of the genes and proteins are generated over the years and have now reached up to a level of saturation, where we need to shift our focus to the more advanced and comprehensive methods and approaches of data analysis and visualization. Even with the availability of enormous literature on this one of the most pressing pathological conditions, a successful cure of the disease seems to be obscure. New treatment plans, like immunotherapy and precision medicine, are being employed for different studies. Nevertheless, their actual benefits to the patients would be known only after the evaluation of clinical data over the next few years. Therefore, we need to look at few fundamental challenges that should be addressed in more depth before we could devise better, rigorous and comprehensive treatment plans and may successfully reach a possible cure of the disease. This article aims at bringing attention towards some fundamental gaps in our approach towards the disease that leads to failure in devising successful therapeutics.

Keywords: Pharmaceutical Sciences

Downloads

Download data is not yet available.

References

1. Shilpa S Sarak’ “BLOOD CANCER” Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org © 2023 JETIR May 2023, Volume 10, Issue 5
2.Maurie Markman, MD, President, Medicine & Science ,Blood cancer. [June 21, 2022]
3. Teresa Hagan Thomas PHD, BA, RN — leukimea Written by Beth Sissons on July 17, 2024
4.Greaves, leukimea in first research and treatment,Nature Reviews Cancer 16 (3),
5. Chronic lymphocytic leukaemia 163-17 Thomas J Kipps, Freda K Stevenson, Catherine J Wu, Carlo M Croce, Graham Packham, William G Wierda, Susan O'brien, John Gribben, Kanti Rai Hajo Zeeb, Maria Blettner Radiation and environmental biophysics. 36 (4), 217-228, 1998
6. Sahithi Maroju, Prathyusha T G, Pravallika A, Amitha U, & Shivkumar Shete. (2021). Leucovorin Rescue Doses in Acute Lymphoblastic Leukemia Patients Receiving High Dose Methotrexate. Int. J. of Clin. Pharm. Med. Sc, 1(4), 159–166.
7. Diagnosis and treatment of chronic lymphocytic leukemia: a review Mazyar Shadman 7. Chronic lymphocytic leukemia: a clinical review Chadi Nabhan, Steven T Rosen Jama 312 (21), 2265-2276,
8. Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky, M Abdul-Hay Blood cancer journal 6 (7), e441-e441, 2016.
9. Acute Lymphoblastic Leukaemia Haematology, Acute Lymphoblastic Leukaemia Original Author(s): Dr Amanda Friend and Dr Carmen Soto Last updated: 15th August 2018
10. Brukinsa (zanubrutinib) - Uses, Side Effects, and More Medically Reviewed by Dena Westphalen, PharmD on Oct 04, 2024 | Written by Ami Ishver, PharmD
11. AHFS Drug Information. 1959-2024, Selected Revisions November 10, 2024. American Society of Health-System
12. Haematological cancer and quality of life: a systematic literature review Priscilla Allart-Vorelli, Bertrand Porro, Fanny Baguet, Aude Michel, Florence Cousson-Gélie, Blood cancer journal 5 (4), e305-e305, 2015
13. Ratnavath Gayathri, Beesam Anuradha, Peteri Pavithra, Katta Varalaxmi, Gorre Madhavi, & Ranga Pushpa. (2022). Case Study of Acute Liver Failure Due to Large B¬-Cell Lymphoma. Future J. Pharm. Health. Sci, 2022, 2(2), 63–67.
14. Leukaemia diagnosis, Barbara j Bain, john wiley &sons,2017, 20. Leukemia and Lymphoma Society. Facts and Statistics Overview (https://www.lls.org/facts-and-statistics/facts-and-statistics-overview#General%252520Blood%252520Cancers). Accessed 4/27/2022.
15. Leukemia: Classification, risk factors, and diagnostic challenges Indunil Karunarathna, K De Alvis, P Gunasena, A Jayawardana, Churpek JE. Familial myelodysplastic syndrome/acute myeloid leukemia. Best Pract Res Clin Haematol. 2017;30(4):287-289. Accessed 5/18/2022.
16. Susmitha N, Venkatesh P. Review on infectious diseases. International Journal of Indigenous Herbs and Drugs. 2022 Jan 30:18-21.
Published
11/02/2025
Statistics
746 Views | 552 Downloads
Citatons
How to Cite
N, H., M, S., Y, P. C., Venugopalaiah , P., & Yerikala, R. (2025). A review on leukemia: advances in diagnosis, treatment and prognosis. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 10(1), 1-6. https://doi.org/10.37022/jiaps.v10i1.650
Section
Review Article(S)